Ukinuta odobrenja, povlačenje serija lijekova, pisma zdravstvenim radnicima i novi lijekovi EU — svakodnevno, automatski. Zadnje ažuriranje: 9. 10. 2026. 08:55
Izvori: promjene pratimo na temelju informacija Agencije za lijekove i medicinske proizvode (HALMED) — rješenja o ukidanju odobrenja, obavijesti o povlačenju serija i pisma zdravstvenim radnicima. Odluke o centralizirano odobrenim lijekovima dolaze iz registra Unije Europske komisije (oznaka EU). Nestašice i liste lijekova HZZO-a ovdje (još) nisu uključene.
br. EU/1/25/1993 · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Intas Third Party Sales 2005, S.L. · denosumab · ATC M05BX04
br. EU/1/25/1987 · Plaque psoriasis
Usgena is indicated for the treatment of moderate to severe plaque psoriasis in adults who… · STADA Arzneimittel AG · ustekinumab · ATC L04AC05
br. EU/1/25/1986 · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Teva GmbH · denosumab · ATC M05BX04
br. EU/1/25/1991 · Lynkuet is indicated for the treatment of moderate to severe vasomotor symptoms (VMS):
- associated with meno… · Bayer AG · elinzanetant · ATC G02CX07
br. EU/1/25/1980 · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · STADA Arzneimittel AG · denosumab · ATC M05BX04
Lekoskop